The APTT response of pregnant plasma to unfractionated heparin

Thrombosis and Haemostasis

Volumn 87, Issue 1, 2002, Pages 92-97

  Chunilal, S D ^a   Young, E ^a   Johnston, M A ^a   Robertson, C ^a   Naguit, I ^a   Stevens, P ^a   Galashan, D ^a   Oskamp, M L ^a   Brennan, B ^a   Ginsberg, J S ^a  

^a JOHN HUNTER HOSPITAL   (Australia)

Author keywords

Activated partial thromboplastin time (APTT); Anti factor Xa activity; Pregnancy; Unfractionated heparin

Indexed keywords

BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 8; FIBRINOGEN; HEPARIN; HEPARIN BINDING PROTEIN; PLASMA PROTEIN; THROMBOPLASTIN; VON WILLEBRAND FACTOR;

ANTICOAGULATION; ARTICLE; BINDING AFFINITY; BLEEDING TENDENCY; BLOOD CLOTTING; COMPARATIVE STUDY; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG OVERDOSE; FEMALE; HUMAN; IN VITRO STUDY; MATERNAL PLASMA; OSTEOPOROSIS; PARTIAL THROMBOPLASTIN TIME; PLASMA PROTEIN BINDING; PREGNANCY; PRIORITY JOURNAL; REGRESSION ANALYSIS; THIRD TRIMESTER PREGNANCY; THROMBOCYTE;

EID: 0036145845     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1612949     Document Type: Article

References (33)

1. Risks to the fetus of anticoagulant therapy during pregnancy
2. Heparin therapy during pregnancy: Risks to the fetus and mother
3. Relationship between the anticoagulant and antithrombotic effects of heparin in experimental venous thrombosis
4. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal vein thrombosis
5. A randomised trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin
6. Establishing a therapeutic range for heparin therapy
7. Monitoring heparin therapy: Relationships between the activated partial thromboplastin time and heparin assays based on ex-vivo heparin samples
8. Drug therapy: Heparin
9. Heparin degradation in endothelial cells
10. Comparison of the non-specific binding of unfractionated heparin and low molecular weight heparin (enoxaparin) to plasma proteins
11. Heparin binding to plasma proteins, an important mechanism for heparin resistance
12. Haemostasis in normal pregnancy
13. Human platelet factor 4 and its C-terminal peptide: Heparin binding and clearance from the circulation
14. Neutralisation of heparin activity by neutrophil lactoferrin
15. Lactoferrin as a sensitive marker of neutrophil activation in normal pregnancies
16. Binding of heparin fractions to von Willebrand factor: Effect of molecular weight and affinity for antithrombin III
17. Beta thromboglobulin and platelet factor 4 levels in pregnancy and pre-eclampsia
18. Changes in haemostasis after stopping the oral combined contraceptive pill: Implications for major surgery
19. Changes in coagulation and anti-coagulation in women taking low dose triphasis oral contraceptive: A controlled comparative 12 month clinical trial
20. Contribution of red blood cells to the saturable mechanism of heparin clearance
21. Retention of antilipemic activity by periodated-oxidised non anticoagulant heparins
22. Rapid physiological coagulation method in determination of fibrinogen
23. Effect of pregnancy on the relationship between concentration and the anticoagulant action of heparin
24. Pharmacokinetics and pharmacodynamics of subcutaneous heparin during the early third trimester of pregnancy
25. Serial hematological changes and pregnancy outcome
26. Heparin and the activated partial thromboplastin time - A difference between the in vitro and in vivo effects and implications for the therapeutic range
27. The variable anticoagulant response to unfractionated heparin in vivo reflects binding to plasma proteins rather than clearance
28. A comparison of low molecular weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis
29. Safety of low molecular weight heparin in pregnancy: A systematic review
30. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumadin
31. Heparin induced thrombocytopenia in patients treated with low molecular weight heparin or unfractionated heparin
32. Adjustment versus fixed doses of low molecular weight heparin (Fragmin) in the treatment of doeep vein thrombosis